StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 0.7
Power Rank trend -> Falling
05/16/2025 16:00:00 EST
Cytokinetics Inc (CYTK)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, CYTK has been trading in a range between $42.92 and $33.04 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Red zone currently. We would avoid this stock.
Upside / Downside Potential
Cytokinetics Inc $CYTK entered a Red zone 54 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $74.5238, a potential upside of 131.94% from the recent price of 32.13. The stock is trading 91.1% (potential upside) below its 52 week high of $61.40 and 1.45 % (potential downside) above its 52 week low of $31.67 - based on the recent price.
Company Summary
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
News
| Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 5 employees, whose employment commenced in April and May, 2025, as a material inducement to their employment. Source: GlobeNewsWire Fri, 16 May 2025 16:00:00 -0400 Sentiment: Neutral |
| Ongoing Investigation: Cytokinetics, Incorporated (CYTK) May Have Misled Shareholders - Levi & Korsinsky Investigates NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. Source: Accesswire Fri, 16 May 2025 10:15:00 -0400 Sentiment: Neutral |
| Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK. Source: Accesswire Fri, 16 May 2025 10:00:00 -0400 Sentiment: Neutral |
| ATTENTION Cytokinetics, Incorporated (CYTK) Investors: Possible Fraud - Contact Levi & Korsinsky Today NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. Source: Accesswire Thu, 15 May 2025 10:30:00 -0400 Sentiment: Neutral |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK). Investors who purchased Cytokinetics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CYTK. Source: Accesswire Thu, 15 May 2025 10:00:00 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 61.4 52 Week Low: 29.31 Beta: 0.81 50 Day MA: 39.5204 200 Day MA: 48.5284 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: 0.891 Forward PE: 0 Trailing PE: 0